Brown, RachelCesewski, EllenFix, JonathanFreudenberger, DevonHiggins, KaraMcMahon, EileenNiba, VanessaPark, HoonPerdomo, GabrielaSeo, AnnaSrivastava, AvantikaTsui, ChristinaWhiteman, AaronZubajlo, RebeccaHuman papillomavirus (HPV) is the leading cause of cervical cancer and the most prevalent sexually transmitted disease worldwide. HPV vaccines require a multi-dose regimen to provide immunity, contributing to low patient compliance. We addressed this problem by formulating biodegradable poly(D,L-lactic-co-glycolic acid) (PLGA) microparticles and assessing their viability for use in controlled-release vaccines. We hypothesized that we could alter fabrication parameters to produce 1-10 μm microparticles in order to encapsulate ovalbumin (OVA) and HPV virus-like particles (VLPs). Microparticles were fabricated using a double emulsion method and used to elicit an immune response in JAWSII cells. Our results contribute to knowledge of vaccine delivery mechanisms and controlled-release technology, and could contribute to the creation of a viable controlled-release HPV vaccine.en-USHuman papillomavirus (HPV)controlled-release vaccinesmicroparticlesGemstone Team EPIDEMICSThesis